RBC Capital Maintains Buy Rating and $30 Price Target for Ocular Therapeutix
RBC Capital has reaffirmed its 'Buy' rating and $30 price target for Ocular Therapeutix, Inc. (NASDAQ: OCUL).
Stocks · News reference
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
RBC Capital has reaffirmed its 'Buy' rating and $30 price target for Ocular Therapeutix, Inc. (NASDAQ: OCUL).
Ocular Therapeutix (NASDAQ:OCUL) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga
Ocular Therapeutix, Inc. announced its financial results for the third quarter ended September 30, 2026, and provided updates on its clinical pipeline, including the upcoming NDA submission for AXPAXLI.
Filed: 2026-11-09 AccNo: 0001104659-26-124159 Size: 191 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Ocular Therapeutix, Inc. announced the grant of inducement equity awards to eight newly hired non-executive employees.